In addition to finding increased levels of FAS in the majority of gastric cancer patients, the present study found that serum FAS levels decreased following therapy in 8 out of 11 gastric cancer patients with pre-and post- therapy measurements of FAS. Here, FAS is linked to gastric cancer.